{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemoglobinuria%2C+Paroxysmal+Nocturnal+%28PNH%29",
    "query": {
      "condition": "Hemoglobinuria, Paroxysmal Nocturnal (PNH)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 67,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemoglobinuria%2C+Paroxysmal+Nocturnal+%28PNH%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T08:20:51.702Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00130000",
      "title": "Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Paroxysmal Hemoglobinuria, Nocturnal"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2005-08-09",
      "completion_date": "2007-06-25",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130000"
    },
    {
      "nct_id": "NCT00867932",
      "title": "Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemoglobinuria, Paroxysmal"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 7,
      "start_date": "2009-10-02",
      "completion_date": "2011-05-12",
      "has_results": true,
      "last_update_posted_date": "2018-10-31",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 3,
      "location_summary": "Orange, California • Pensacola, Florida • Memphis, Tennessee",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00867932"
    },
    {
      "nct_id": "NCT06524726",
      "title": "The International PNH Interest Group PNH Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "International PNH Interest Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2000,
      "start_date": "2024-05-10",
      "completion_date": "2029-05-10",
      "has_results": false,
      "last_update_posted_date": "2024-07-29",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 1,
      "location_summary": "Altamonte Springs, Florida",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06524726"
    },
    {
      "nct_id": "NCT00975975",
      "title": "Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Myelodysplasia",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Disease",
        "Multiple Myeloma",
        "Myelofibrosis",
        "Anemia, Aplastic",
        "Hemoglobinuria, Paroxysmal"
      ],
      "interventions": [
        {
          "name": "Basiliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2009-09",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-02-26",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00975975"
    },
    {
      "nct_id": "NCT03030183",
      "title": "Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Zilucoplan (RA101495)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ra Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-04-17",
      "completion_date": "2018-03-28",
      "has_results": true,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Los Angeles, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03030183"
    },
    {
      "nct_id": "NCT02946463",
      "title": "ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Eculizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 272,
      "start_date": "2016-12-12",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Whittier, California • Fort Worth, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02946463"
    },
    {
      "nct_id": "NCT01294891",
      "title": "Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheologic Disease",
        "Sickle Cell Disease",
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "Imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-02",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-10-28",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01294891"
    },
    {
      "nct_id": "NCT00039923",
      "title": "Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Paroxysmal Hemoglobinuria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2002-06",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00039923"
    },
    {
      "nct_id": "NCT00122330",
      "title": "Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemoglobinuria, Paroxysmal"
      ],
      "interventions": [
        {
          "name": "eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2004-10",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2006-12-04",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00122330"
    },
    {
      "nct_id": "NCT03472885",
      "title": "Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        },
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2018-05-08",
      "completion_date": "2023-01-05",
      "has_results": true,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-06-10T08:20:51.702Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Cleveland, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472885"
    }
  ]
}